Transmission of drug-resistant HIV-1 in Europe remains limited to single classes

Background:The spread of drug-resistant HIV-1 might compromise the future success of current first-line regimens. Objective:To analyse the extent and impact of transmission of drug-resistant HIV-1 variants in Europe. Design and methods:The European prospective programme (SPREAD) collected demographic, clinical and virological data from 1245 HIV-1-infected individuals in 17 countries diagnosed in 2002–2003. The potential impact of transmitted drug resistance mutations (TDRMs) on therapy response was determined by using genotypic interpretation algorithms. Results:The overall prevalence of viruses with drug-resistance mutations was 9.1% [96/1050; 95% confidence interval: 7.5–11.1]. The majority (71%) harboured only a single amino acid substitution with limited effect on predicted drug susceptibility. Mutations associated with resistance to nucleoside reverse transcriptase inhibitors were observed most frequently [57/1050 (5.4%)], followed by mutations related to protease inhibitors [32/1050 (3.0%)] and mutations related to non-nucleoside reverse transcriptase inhibitors (NNRTIs) [27/1050 (2.6%)].In some cases, however, resistance was quite extensive. Four individuals were infected with viruses with reduced susceptibility to all nucleoside reverse transcriptase inhibitors, 3 to all protease inhibitors and 20 to both NNRTIs. Remarkably, in one individual, the resistance pattern was so extensive that none of the available current antiretroviral drugs was predicted to be fully active. Conclusion:The prevalence of TDRM-HIV is quite prominent (9.1%) but did not increase in comparison with a large retrospective European study. Particularly the presence of single NNRTI mutations may impact the efficacy of the first-line regimens. Continuous prospective monitoring remains indicated to explore the patterns and factors contributing to the transmission of TDRMs as well as the potential clinical consequences.

[1]  J. Corbeil,et al.  Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy , 1994, Journal of virology.

[2]  M. Segal,et al.  Persistence of primary drug resistance among recently HIV-1 infected adults , 2004, AIDS.

[3]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[4]  Martin Bland,et al.  An Introduction to Medical Statistics , 1987 .

[5]  Simon D W Frost,et al.  Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. , 2003, The Journal of infectious diseases.

[6]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[7]  Christine Hogan,et al.  Tracking the Prevalence of Transmitted Antiretroviral Drug-Resistant HIV-1: A Decade of Experience , 2006, Journal of acquired immune deficiency syndromes.

[8]  Alessandro Cozzi-Lepri,et al.  Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy , 2004, AIDS.

[9]  Hauke Walter,et al.  Detection of minor populations of drug-resistant HIV-1 in acute seroconverters , 2005, AIDS.

[10]  J. Kahn,et al.  Time trends in primary HIV-1 drug resistance among recently infected persons. , 2002, JAMA.

[11]  Tulio de Oliveira,et al.  An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..

[12]  Rodrigo Lopez,et al.  Multiple sequence alignment with the Clustal series of programs , 2003, Nucleic Acids Res..

[13]  M. Wainberg,et al.  The Influence of Protease Inhibitor Resistance Profiles on Selection of HIV Therapy in Treatment-Naive Patients , 2003, Antiviral therapy.

[14]  D. Pillay,et al.  Evolution of Transmitted HIV-1 with Drug-Resistance Mutations in the Absence of Therapy: Effects on Cd4+ T-Cell Count and HIV-1 Rna Load , 2006, Antiviral therapy.

[15]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[16]  Bluma G. Brenner,et al.  Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection , 2002, Journal of Virology.

[17]  D. Richman,et al.  Update of the drug resistance mutations in HIV-1: December 2010. , 2010, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[18]  W. Heneine,et al.  The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. , 2004, The Journal of infectious diseases.

[19]  A. Vandamme,et al.  A Genotypic Drug Resistance Interpretation Algorithm that Significantly Predicts Therapy Response in HIV-1-Infected Patients , 2001, Antiviral therapy.

[20]  M. Kozal,et al.  Antiretroviral resistance and high-risk transmission behavior among HIV-positive patients in clinical care , 2004, AIDS.

[21]  Elizabeth Connick,et al.  Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.

[22]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[23]  F. Brun-Vézinet,et al.  French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002 , 2005, Journal of acquired immune deficiency syndromes.

[24]  Klaus Korn,et al.  The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes , 2006, Journal of acquired immune deficiency syndromes.

[25]  D. Pillay,et al.  Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study , 2005, BMJ : British Medical Journal.

[26]  V. Calvez,et al.  Persistence of Multidrug-Resistant HIV-1 without Antiretroviral Treatment 2 Years after Sexual Transmission , 2003, Antiviral therapy.

[27]  Diana D. Huang,et al.  Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. , 2002, AIDS research and human retroviruses.

[28]  M. Greenwood.  An Introduction to Medical Statistics , 1932, Nature.

[29]  Amalio Telenti,et al.  Update of the Drug Resistance Mutations in HIV-1: 2005. , 2005, Topics in HIV medicine : a publication of the International AIDS Society, USA.